Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any ...
The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
En qué bolsa de valores cotiza Novo Nordisk ADR? Las acciones de Novo Nordisk ADR cotizan y se negocian en la bolsa de valores Nueva York. ¿Cuál es el símbolo bursátil de Novo Nordisk ADR?
Novo Nordisk’s annual results are out and they show the Danish pharmaceutical juggernaut earnt 290.4 billion Danish kroner last year (A$64 billion) — up 25%. Novo Nordisk boasts 45 million ...
Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This company announcement discloses the data of the transaction(s ...
Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists in type 2 diabetes, has started phase III trials. If it reaches the market, the oral formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback